The Zhitong Finance App learned that Goldman Sachs released a research report saying that the revenue growth forecast for the second quarter of JD Health (06618.HK) is generally in line with market expectations. Although the 618 shopping festival's performance is relatively lackluster, with the support of core categories continuing to gain market share, it is currently predicted that revenue for the second quarter will increase 18% year-on-year. Goldman Sachs currently predicts an adjusted operating profit margin of 7.1% for the second quarter of JD Health, which continues to improve year over year. The bank also expects its growth to accelerate in the second half of the year. The rating remains “buy”, with a target price of HK$65.

The Zhitong Finance App learned that Goldman Sachs released a research report saying that the revenue growth forecast for the second quarter of JD Health (06618.HK) is generally in line with market expectations. Although the 618 shopping festival's performance is relatively lackluster, with the support of core categories continuing to gain market share, it is currently predicted that revenue for the second quarter will increase 18% year-on-year. Goldman Sachs currently predicts an adjusted operating profit margin of 7.1% for the second quarter of JD Health, which continues to improve year over year. The bank also expects its growth to accelerate in the second half of the year. The rating remains “buy”, with a target price of HK$65.